Evidence map›Paper›PMID 38771834›Full record

Trial reportPloS one2024

Using 30-day modified rankin scale score to predict 90-day score in patients with intracranial hemorrhage: Derivation and validation of prediction model.

William L Baker, Mukul Sharma, Alexander Cohen, Mario Ouwens, Mary J Christoph, Bruce Koch, Timothy E Moore, Garrett Frady, Craig I Coleman

Abstract readValidation StudyRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

William L BakerUniversity of Connecticut School of Pharmacy, Storrs, CT, United States of America.
Mukul SharmaDivision of Neurology, Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Alexander CohenGuy's and St. Thomas' Hospitals, King's College London, London, United Kingdom.
Mario OuwensMedical and Payer Evidence, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom.
Mary J ChristophAstraZeneca Pharmaceuticals, Wilmington, DE, United States of America.
Bruce KochAstraZeneca Pharmaceuticals, Wilmington, DE, United States of America.
Timothy E MooreStatistical Consulting Services, Center for Open Research Resources & Equipment, University of Connecticut, Storrs, CT, United States of America.
Garrett FradyDepartment of Statistics, University of Connecticut, Storrs, CT, United States of America.
Craig I ColemanUniversity of Connecticut School of Pharmacy, Storrs, CT, United States of America.ORCID 0000-0003-4868-7158

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Whether 30-day modified Rankin Scale (mRS) scores can predict 90-day scores is unclear. This study derived and validated a model to predict ordinal 90-day mRS score in an intracerebral hemorrhage (ICH) population using 30-day mRS values and routinely available baseline variables. Adults enrolled in the Antihypertensive Treatment of Acute Cerebral Hemorrhage-2 (ATACH-2) trial between May 2011 and September 2015 with acute ICH, who were alive at 30 days and had mRS scores reported at both 30 and 90 days were included in this post-hoc analysis. A proportional odds regression model for predicting ordinal 90-day mRS scores was developed and internally validated using bootstrapping. Variables in the model included: mRS score at 30 days, age (years), hematoma volume (cm3), hematoma location (deep [basal ganglia, thalamus], lobar, or infratentorial), presence of intraventricular hemorrhage (IVH), baseline Glasgow Coma Scale (GCS) score, and National Institutes of Health Stroke Scale (NIHSS) score at randomization. We assessed model fit, calibration, discrimination, and agreement (ordinal, dichotomized functional independence), and EuroQol-5D ([EQ-5D] utility weighted) between predicted and observed 90-day mRS. A total of 898/1000 participants were included. Following bootstrap internal validation, our model (calibration slope = 0.967) had an optimism-corrected c-index of 0.884 (95% CI = 0.873-0.896) and R2 = 0.712 for 90-day mRS score. The weighted ĸ for agreement between observed and predicted ordinal 90-day mRS score was 0.811 (95% CI = 0.787-0.834). Agreement between observed and predicted functional independence (mRS score of 0-2) at 90 days was 74.3% (95% CI = 69.9-78.7%). The mean ± SD absolute difference between predicted and observed EQ-5D-weighted mRS score was negligible (0.005 ± 0.145). This tool allows practitioners and researchers to utilize clinically available information along with the mRS score 30 days after ICH to reliably predict the mRS score at 90 days.

Indexed as

Intracranial HemorrhagesAgedAged, 80 and overCerebral HemorrhageFemaleGlasgow Coma ScaleHumansMaleMiddle AgedPrognosisSeverity of Illness Index

Identifiers

PMID38771834
PMCPMC11108121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.